Please login to the form below

Not currently logged in
Email:
Password:

emphysema

This page shows the latest emphysema news and features for those working in and with pharma, biotech and healthcare.

GSK gets maintenance indication for Trelegy

GSK gets maintenance indication for Trelegy

Specifically, the new approval is for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema, which could make Trelegy a

Latest news

  • Shire receives FDA nod for self-infusion of Glassia Shire receives FDA nod for self-infusion of Glassia

    Shire's emphysema therapy Glassia has received FDA approval for an expanded label, marking the first time that patients can self-infuse at home. ... Glassia, an alpha-1 proteinase inhibitor, is licensed for the treatment of adults with emphysema due to

  • FDA approves Boehringer COPD spray Striverdi Respimat FDA approves Boehringer COPD spray Striverdi Respimat

    Licence from US regulator will also allow it to treat chronic bronchitis or emphysema.  . ... The FDA said it can now be used to treat COPD patients, including those with chronic bronchitis or emphysema to help unblock airways, but the regulator wants

  • GSK wins US approval for Seretide successor Breo Ellipta GSK wins US approval for Seretide successor Breo Ellipta

    The FDA licensed Breo Ellipta to treat airflow obstruction in patients with COPD, including chronic bronchitis and emphysema, and said it can also be used to reduce exacerbations of COPD.

  • GSK submits COPD drug in US and EU GSK submits COPD drug in US and EU

    including chronic bronchitis and emphysema.

  • Drug delivery

    Commercialisation. 134. Halozyme Therapeutics/Intrexon Corp. rHuPH20 enzyme drug delivery. technology for COPD and genetic emphysema.

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Raising Awareness: It’s World COPD Day today!

    Damage to the delicate walls of the air sacs in the lungs causes emphysema and the lungs lose their normal elasticity. ... The two most commonly recognised clinical phenotypes of COPD are emphysema and chronic bronchitis, with the majority of COPD

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics